LTGO vs AKTS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LTGO · Latigo Biotherapeutics$13.00 ▼ 1.81%
AKTS · Aktis Oncology$16.15 ▼ 1.52%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LTGO -28.8%
- AKTS -33.1%
Head to head
| Metric | LTGO | AKTS |
|---|---|---|
| Price | $13.00 | $16.15 |
| Change today | ▼ 1.81% | ▼ 1.52% |
| Market cap | $861.89M | $901.14M |
| Return, 3 months | -40.9% | -37.8% |
| Return, year to date | – | – |
| Return, 1 year | – | – |
| P/E (TTM) | – | – |
| P/B | 2.2 | 2.0 |
| P/E percentile vs own 5y | 89th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +147.3% |
| Net profit growth (YoY) | +15.5% | -92.7% |
| Gross margin | – | – |
| Operating margin | – | -837.5% |
| Net margin | – | -706.8% |
| Return on equity | -27.2% | -53.6% |
| Analyst target vs. price | +343.6% | +126.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 41 | 46 |
| 30-day volatility | 84.6% | 62.9% |
| Max drawdown, 1 year | -49.6% | -54.7% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AKTS is the largest of the group by market value.
- AKTS has been the calmest stock over the last 30 days.